丙型肝炎相关肝细胞癌肝移植后生存率与病毒血症状态相当
该研究基于UNOS登记数据,分析2015年3月31日至2021年6月30日期间接受肝移植的成人丙型肝炎相关肝细胞癌患者,按受者(活动性vs治愈丙肝)和供者(HCV+ vs HCV-)病毒血症状态评估移植后生存。摘要未报告具体生存数值与统计结果。
研究设计与样本
- 利用UNOS登记数据库,纳入2015年3月31日至2021年6月30日接受肝移植且有受者/供者HCV核酸检测结果的成人HCV相关肝细胞癌患者。
- 排除急性肝衰竭、多器官联合移植、既往肝移植及受者或供者NAT结果缺失者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Direct-acting antiviral (DAA) therapy for the treatment of chronic hepatitis C virus (HCV) infection is efficacious and well-tolerated in the post-liver transplant (LT) setting, prompting increased use of donors with HCV infection in patients waitlisted for LT.1,2 Although the incidence of nonviral hepatocellular carcinoma (HCC) is rising, HCV remains the most common risk factor for HCC among patients listed for LT in the United States.3 The use and outcomes of HCV-infected donors among patients with active HCV viremia waitlisted for (HCV-HCC) is lacking. Our aim was to evaluate post-LT survival among patients with HCV-HCC based on both recipient (active vs cured HCV) and donor (HCV+ vs HCV-) viremic status. Using the United Network for Organ Sharing (UNOS) registry, we analyzed all adult patients with HCV-HCC who underwent LT and had available recipient/donor HCV nucleic acid test (NAT) results from March 31, 2015 (date UNOS began reporting donor NAT) through June 30, 2021. Patients with acute liver failure, simultaneous organ transplant, previous LT, and those missing recipient and/or donor NAT results were excluded.
引用
- Lymberopoulos P, Shaikh A, Rich NE, et al. Comparable Survival for Hepatitis C-Related Hepatocellular Carcinoma After Liver Transplantation Irrespective of Viremic Status. Clin Gastroenterol Hepatol. 2022. PMID: 35346850. doi:10.1016/j.cgh.2022.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。